Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38660114 | 0.84 | ALDH1A1 (0.58) | LMNAKMT2AALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL22216884 | 0.83 | LMNA (0.47) | LMNAKMT2AALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL5373950 | 0.83 | LMNA (0.51) | LMNAKMT2AALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL2390426 | 0.83 | LMNA (0.51) | LMNAKMT2AALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL19381723 | 0.83 | ERN1 (0.44) | LMNAKMT2AALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL38659181 | 0.81 | ALDH1A1 (0.71) | LMNAALDH1A1CYP1A2CYP2C19ERN1 | |
| SCHEMBL4354925 | 0.80 | THRB (0.55) | LMNAKMT2AALDH1A1THRBHTT | |
| SCHEMBL2128796 | 0.80 | LMNA (0.45) | LMNAKMT2AALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL5388061 | 0.80 | LMNA (0.45) | LMNAKMT2AALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL5430162 | 0.80 | LMNA (0.53) | LMNAKMT2AALDH1A1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016029146-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON (US) | 2016-02-25 | — | — | WO | claimed |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | UNIVERSITY OF WASHINGTON (US) | 2021-02-09 | — | — | US | disclosed |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON | 2017-09-28 | — | — | US | disclosed |
| US-6320051-B1 | AMINO(NH) OR OXYGEN(O) SUBSTITUTED, ENZYME INHIBITORS OF STAPHLOCCOCUS AUREUS METHIONYL T-RNA SYNTHETASE (MRS); ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2001-11-20 | — | — | US | disclosed |
| EP-1084110-A1 | QUINOLONES USED AS MRS INHIBITORS AND BACTERICIDES | SMITHKLINE BEECHAM PLC (GB) | 2001-03-21 | — | — | EP | disclosed |
| WO-2000071524-A1 | 2-NH-PYRIDONES AND PYRIMIDONES AS MRS INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-30 | — | — | WO | disclosed |
| WO-2000071522-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS METHIONYL T-RNA SYNTHETASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-30 | — | — | WO | disclosed |
| WO-1999055677-A1 | QUINOLONES USED AS MRS INHIBITORS AND BACTERICIDES | SMITHKLINE BEECHAM PLC (GB) | 1999-11-04 | — | — | WO | disclosed |
| US-4015016-A | [(2-Alkoxyberzylidine)amino]quanidines and their anticoccidal use | THE DOW CHEMICAL COMPANY (US) | 1977-03-29 | — | — | US | disclosed |
| US-3973039-A | [(2-Alkoxybenzylidine)amino]guanidines and their anticoccidial use | THE DOW CHEMICAL COMPANY (US) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | AARS1, MTR, GARS1 | LMNA 3835/4885KMT2A 1195/4885ALDH1A1 2330/4885 |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | AARS1, MTR, GARS1 | LMNA 3835/4885KMT2A 1195/4885ALDH1A1 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.